This activity was designed to improve the knowledge and competence of clinicians with respect to biomarker testing, selection of first-line checkpoint inhibitor therapy, and management of immunotherapy-related adverse events in patients with advanced NSCLC.
Upon completion of this activity, participants should be better able to:
Chair and Professor, Medical Oncology
University Hospital of Lausanne
Lausanne, Switzerland
Honorary Chair, Department of Pathology
Aberdeen University School of Medicine
Aberdeen Royal Infirmary
Foresterhill, Aberdeen,
Scotland, United Kingdom
Professor, Hematology and Medical Oncology
Roberto C. Goizueta Chair, Cancer Research
Director, Division of Medical Oncology
Assistant Dean, Cancer Research
Deputy Director, Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia, United States
Featured RMEI CE Activities – Earn CE Credit(s)
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
